1. Home
  2. JEQ vs AGEN Comparison

JEQ vs AGEN Comparison

Compare JEQ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JEQ
  • AGEN
  • Stock Information
  • Founded
  • JEQ 1990
  • AGEN 1994
  • Country
  • JEQ United States
  • AGEN United States
  • Employees
  • JEQ N/A
  • AGEN N/A
  • Industry
  • JEQ Air Freight/Delivery Services
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • JEQ Consumer Discretionary
  • AGEN Health Care
  • Exchange
  • JEQ Nasdaq
  • AGEN Nasdaq
  • Market Cap
  • JEQ 99.8M
  • AGEN 87.7M
  • IPO Year
  • JEQ N/A
  • AGEN 2000
  • Fundamental
  • Price
  • JEQ $7.35
  • AGEN $5.16
  • Analyst Decision
  • JEQ
  • AGEN Buy
  • Analyst Count
  • JEQ 0
  • AGEN 4
  • Target Price
  • JEQ N/A
  • AGEN $13.00
  • AVG Volume (30 Days)
  • JEQ 32.0K
  • AGEN 1.1M
  • Earning Date
  • JEQ 01-01-0001
  • AGEN 08-07-2025
  • Dividend Yield
  • JEQ 7.05%
  • AGEN N/A
  • EPS Growth
  • JEQ N/A
  • AGEN N/A
  • EPS
  • JEQ N/A
  • AGEN N/A
  • Revenue
  • JEQ N/A
  • AGEN $99,524,000.00
  • Revenue This Year
  • JEQ N/A
  • AGEN $12.69
  • Revenue Next Year
  • JEQ N/A
  • AGEN N/A
  • P/E Ratio
  • JEQ N/A
  • AGEN N/A
  • Revenue Growth
  • JEQ N/A
  • AGEN N/A
  • 52 Week Low
  • JEQ $4.99
  • AGEN $1.38
  • 52 Week High
  • JEQ $6.39
  • AGEN $18.74
  • Technical
  • Relative Strength Index (RSI)
  • JEQ 51.59
  • AGEN 53.94
  • Support Level
  • JEQ $7.24
  • AGEN $4.78
  • Resistance Level
  • JEQ $7.62
  • AGEN $6.20
  • Average True Range (ATR)
  • JEQ 0.09
  • AGEN 0.52
  • MACD
  • JEQ -0.02
  • AGEN -0.04
  • Stochastic Oscillator
  • JEQ 50.00
  • AGEN 42.20

About JEQ abrdn Japan Equity Fund Inc.

Aberdeen Japan Equity Fund Inc is a United States-based closed-end diversified management investment company. Its investment objective is to outperform over the long term, on a total return basis (including appreciation and dividends), the Tokyo Stock Price Index ("TOPIX"). The fund seeks to achieve its investment objective by investing a majority of its assets, in equity securities of companies listed on the Tokyo Stock Exchange or listed on the over-the-counter market in Japan or listed on other stock exchanges in Japan. The portfolio of investments is spread across Consumer Discretionary, Industrials, Information Technology, Financials, and other sectors.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: